Monday, Nov 23, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | Hyderabad | Hyderabad Biotech Startup Reverses Chronic Liver Failure In Preclinical Trials With Novel Stem Cell Therapy

Hyderabad biotech startup reverses chronic liver failure in preclinical trials with novel stem cell therapy

Tulsi Therapeutics, a biotech startup from Hyderabad, has reversed chronic liver failure in animal trials using Tulsi-28X, a first-in-class stem cell–exosome therapy. The innovation showed 100% survival and fibrosis reversal, setting the stage for human clinical trials.

By Yuvraj Akula
Updated On - 24 July 2025, 02:01 PM
Hyderabad biotech startup reverses chronic liver failure in preclinical trials with novel stem cell therapy
whatsapp facebook twitter telegram

Hyderabad: In a potential game-changer for people suffering from chronic liver disease, Tulsi Therapeutics, a startup incubated at ASPIRE-BioNEST, University of Hyderabad (UoH), has successfully reversed chronic liver failure in preclinical trials.

Using the novel stem cell–exosome combination therapy, the start-up demonstrated 100 percent of the animals treated with Tulsi-28X, an investigational product, showed reversal of liver fibrosis (indicating liver regeneration) resulting in zero deaths, compared to only 14 percent reversal and 43 percent deaths in the untreated control group.

Also Read

  • Hyderabad: Doctors successfully perform critical liver transplant

The preclinical trial was conducted in collaboration with global experts including Dr. Naga Chalasani (Indiana University, USA) and Dr. Ajay Duseja (PGIMER, Chandigarh). According to the start-up, Tulsi Therapeutics is also the world’s first biotech company developing dual stem cell–exosome biologics. Tulsi-28X works by secreting regenerative proteins and growth factors, stimulating the repair of diseased liver tissue.

The investigational product, Tulsi-28X, is a first-in-class regenerative therapy derived from Wharton’s Jelly mesenchymal stem cells and their native exosomes—a combination never before tested in any animal model worldwide. While conceptualized in the United States, the platform was entirely developed in India through three years of intensive research at ASPIRE-BioNEST.

“This is a significant milestone for India’s biotech industry. While human trials are the next challenge, this study opens doors to a new class of biologics in liver disease,” said Dr. Sairam Atluri, Founder & CEO Tulsi Therapeutics.

Key results were presented at the prestigious AASLD 2024 Liver Conference in San Diego and accepted for publication in the Journal of Regenerative Medicine.

“We are committed to developing world-class yet affordable regenerative solutions. Our next step is to take Tulsi-28X into human clinical trials in collaboration with Nizam’s Institute of Medical Sciences (NIMS),” said Dr. Ravi Bonthala, Chief Scientific Officer Tulsi Therapeutics.

Chronic liver failure remains a serious public health concern in India, contributing to nearly 20 percent of global liver-related deaths. With transplantation being the only current treatment, Tulsi-28X represents a potential paradigm shift.

“This milestone highlights how India’s innovation ecosystem—anchored by institutions like the UoH and enabled by BIRAC and incubators like ASPIRE-BioNEST—is capable of delivering breakthrough global biotech products,” said Prof. BJ Rao, Vice Chancellor, UoH.

Join Our Whatsapp Channel
  • Follow Us :
As preferred source
  • Tags
  • ASPIRE-BioNEST
  • liver failure
  • Tulsi Therapeutics
  • University of Hyderabad

Related News

  • IIT Hyderabad Director B S Murty urges youth to help build a developed India

    IIT Hyderabad Director B S Murty urges youth to help build a developed India

  • 31 UoH researchers feature in Stanford-Elsevier world’s top 2 pc scientists list

    31 UoH researchers feature in Stanford-Elsevier world’s top 2 pc scientists list

  • Dilshada Raihan elected University of Hyderabad Students’ Union president

    Dilshada Raihan elected University of Hyderabad Students’ Union president

  • Hyderabad: UoH student union poll results today

    Hyderabad: UoH student union poll results today

Latest News

  • Opinion: The digital brain—powered by purpose

    14 minutes ago
  • Pochettino suffers nightmare start as Manchester United lose 4-0 to Liverpool

    16 minutes ago
  • Four centuries highlight HCA C-Division league

    22 minutes ago
  • Agile Valley Warriors clinch Telangana Premier Golf League 2026 title

    26 minutes ago
  • Telugu Black Hawks clinch bronze at CAVA club championship

    31 minutes ago
  • Tilak Varma’s century in vain as India A lose to Pakistan A

    35 minutes ago
  • Liverpool rout Manchester United in Premier League as Pochettino suffers nightmare start

    47 minutes ago
  • Guard of honour for Asaduddin Owaisi in Saharanpur triggers political controversy

    57 minutes ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam

Telangana Today App